$1.09
+0.00 (+0.00%)
Open$1.12
Previous Close$1.09
Day High$1.13
Day Low$1.07
52W High$4.19
52W Low$0.81
Volume—
Avg Volume122.1K
Market Cap12.60M
P/E Ratio—
EPS$-1.49
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,891.7% upside
Current
$1.09
$1.09
Target
$32.61
$32.61
$25.28
$32.61 avg
$46.79
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.43M | 2.52M | 2.31M |
| Net Income | 150.5K | 215.1K | 194.2K |
| Profit Margin | 6.2% | 8.5% | 8.4% |
| EBITDA | 295.2K | 302.7K | 296.9K |
| Free Cash Flow | 147.2K | 165.8K | 140.8K |
| Rev Growth | +21.7% | -7.9% | -0.3% |
| Debt/Equity | 0.76 | 0.80 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |